Presented by Suzanne George, MD, Center for Sarcoma and Bone Oncology, Dana-Farber/Brigham and Women's Cancer Center, and Harvard Medical School, Boston, Massachusetts.
J Natl Compr Canc Netw. 2017 May;15(5S):733-736. doi: 10.6004/jnccn.2017.0087.
Soft tissue sarcomas comprise multiple histologic subtypes, occur at a number of anatomic sites, and require individualized treatment. Over the past 5 years, 4 new drugs were approved for sarcoma, most of which are driven by histology or the anticipated response to treatment. Surgical resection remains the primary treatment for resectable tumors. For unresectable or metastatic disease, doxorubicin remains the backbone of chemotherapy, but other agents have improved on its single-agent efficacy. Chief among them is olaratumab, which, in combination with doxorubicin, is preferred over doxorubicin alone in the updated NCCN Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma.
软组织肉瘤包括多种组织学亚型，发生于多个解剖部位，需要个体化治疗。在过去的 5 年中，有 4 种新的药物被批准用于肉瘤治疗，其中大多数是根据组织学或预期的治疗反应来选择的。手术切除仍然是可切除肿瘤的主要治疗方法。对于不可切除或转移性疾病，多柔比星仍然是化疗的基础，但其他药物在其单药疗效方面有所提高。其中最重要的是奥拉单抗，在更新的 NCCN 肿瘤临床实践指南中，其联合多柔比星治疗比单独使用多柔比星更受推荐。
